United States · FDA National Drug Code directory
VPRIV
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 54092-701_27f96d8e-a6e0-4743-a76c-00f979bfb5f7
- Product NDC
- 54092-701
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- velaglucerase alfa
- Labeler
- Takeda Pharmaceuticals America, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20100226
- Source listing expiry
- 20261231
Source-listed ingredients
- VELAGLUCERASE ALFA — 2.5 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, GLASS in 1 BOX (54092-701-04) / 4 mL in 1 VIAL, GLASS · 54092-701-04
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →